Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Crisaborole
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Derm-Biome’s newly developed compounds far outperformed crisaborole blocking the development of skin inflammation in a mouse model of atopic dermatitis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 10, 2022
Lead Product(s) : Crisaborole
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crisaborole
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 28, 2022
Lead Product(s) : Crisaborole
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crisaborole
Therapeutic Area : Dermatology
Study Phase : Phase IV
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 20, 2022
Lead Product(s) : Crisaborole
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crisaborole
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Padagis Confirms First-to-File Patent Challenge For Generic Version Of Eucrisa®
Details : Padagis's Paragraph IV Abbreviated New Drug Application filing for crisaborole ointment 2%, asserting patents listed in Orange Book for Eucrisa®. Padagis's first-to-file ANDA for generic version of Eucrisa® (crisaborole ointment 2%) for treatment of at...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2021
Lead Product(s) : Crisaborole
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crisaborole
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Characterizing Skin Microbiome Change in Atopic Dermatitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 16, 2021
Lead Product(s) : Crisaborole
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crisaborole
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2020
Lead Product(s) : Crisaborole
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crisaborole
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 24, 2020
Lead Product(s) : Crisaborole
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crisaborole
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Topical Crisaborole in Patients with Alopecia Areata
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 06, 2020
Lead Product(s) : Crisaborole
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crisaborole
Therapeutic Area : Dermatology
Study Phase : Phase IV
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 02, 2020
Lead Product(s) : Crisaborole
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crisaborole
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 16, 2019
Lead Product(s) : Crisaborole
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable